We could not find any results for:
Make sure your spelling is correct or try broadening your search.
WINNERSH, England, Dec. 11 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VERLSE:Nasdaq:LSE:VNLS) today announced that it has started a Phase I trial of V24343, a CB1 antagonist, as a potential...
WINNERSH, England, Nov. 21 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VER)(NASDAQ:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...
WINNERSH, England, Nov. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Novartis has...
WINNERSH, England, Nov. 2 /PRNewswire/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...
WINNERSH, U.K., Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VER) (NASDAQ:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...
WINNERSH, England, Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the...
- Vernalis Delivers on Significant Clinical Milestones and Establishes Commercial Operation - WINNERSH, England, Sept. 12 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS...
CHADDS FORD, Pa. and WINNERSH, U.K., July 19 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) and Vernalis plc (NASDAQ:VNLS) (LONDON: VER) today announced that Endo...
WINNERSH, England, June 19 /PRNewswire-FirstCall/ -- Vernalis plc (NASDAQ:VNLS)(LSE:VER), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions